Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies

Arthritis and Rheumatism

Volumn 62, Issue 9, 2010, Pages 2787-2795

  Shah, Ami A ^a   Rosen, Antony ^a   Hummers, Laura ^a   Wigley, Fredrick ^a   Casciola Rosen, Livia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; AZATHIOPRINE; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; DNA TOPOISOMERASE VIII; ISOMERASE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RNA POLYMERASE; RNA POLYMERASE ANTIBODY; UNCLASSIFIED DRUG; ANTI-EXTRACTABLE NUCLEAR ANTIGEN ANTIBODIES; ANTINUCLEAR ANTIBODY;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER TISSUE; CENTROMERE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTRADUCTAL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; NEOPLASM; ONSET AGE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SKIN CARCINOMA; SKIN SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; STAINING; TONGUE CARCINOMA; TUMOR LOCALIZATION; UTERUS CARCINOMA; VAGINA CARCINOMA; BLOOD; COMORBIDITY; ENZYMOLOGY; IMMUNOLOGY; MIDDLE AGED; NEOPLASMS; SCLERODERMA, SYSTEMIC; TIME; UNITED STATES;

AGE OF ONSET; AGED; ANTIBODIES, ANTINUCLEAR; CENTROMERE; COMORBIDITY; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; MALE; MARYLAND; MIDDLE AGED; NEOPLASMS; RNA POLYMERASE I; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC; TIME FACTORS;

EID: 77956390135     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27549     Document Type: Article

References (47)

1. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460-4.
2. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33: 1113-6. (Pubitemid 43825461)
3. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31. (Pubitemid 36886406)
4. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985;12:1136-9. (Pubitemid 16166459)
5. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76: 910-4.
6. Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum 1985;28:1336-40.
7. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007;66:551-3. (Pubitemid 46580482)
8. Hasegawa M, Sato S, Sakai H, Ohashi T, Takehara K. Systemic sclerosis revealing T-cell lymphoma. Dermatology 1999;198:75-8. (Pubitemid 29086341)
9. Juarez M, Marshall R, Denton C, Evely R. Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology (Oxford) 2008;47:1734-5.
10. Reyes CM, Rudinskaya A, Kloss R, Girardi M, Lazova R. Scleroderma- like illness as a presenting feature of multiple myeloma and amyloidosis. J Clin Rheumatol 2008;14:161-5.
11. Forbes AM, Woodrow JC, Verbov JL, Graham RM. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989;28:65-9.
12. Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004;23:516-22. (Pubitemid 39562258)
13. Lu TY, Hill CL, Pontifex EK, Roberts-Thomson PJ. Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. Rheumatol Int 2008;28:895-9.
14. Scope A, Sadetzki S, Sidi Y, Barzilai A, Trau H, Kaufman B, et al. Breast cancer and scleroderma. Skinmed 2006;5:18-24.
15. Bachleitner-Hofmann T, Machold K, Knobler R, Drach J, Grumbeck E, Gisslinger H. Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma. Clin Exp Rheumatol 2002;20:85-8. (Pubitemid 34213741)
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Commit- tee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
17. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
18. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6. (Pubitemid 24031593)
19. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
21. Knudson RJ, Kaltenborn WT, Knudson DE, Burrows B. The single-breath carbon monoxide diffusing capacity: reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987;135:805-11. (Pubitemid 17055505)
22. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004;43:461-6. (Pubitemid 38489363)
23. Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis 2006;65:1028-32. (Pubitemid 44133264)
24. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-9. (Pubitemid 24312647)
25. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 2001;134: 1087-95.
26. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357: 96-100. (Pubitemid 32094911)
27. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90.
28. Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009;116:981-989.e1.
29. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 2008;8:970-6.
30. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 2008;105:8061-6. (Pubitemid 351904708)
31. Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother 2008;20:278-81. (Pubitemid 351797071)
32. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18. (Pubitemid 43247141)
33. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4. (Pubitemid 35231542)
34. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-46.
35. Giaccone G, van Ark-Otte J, Scagliotti G, Capranico G, van der Valk P, Rubio G, et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1995;1264:337-46. (Pubitemid 26014968)
36. Lynch BJ, Bronstein IB, Holden JA. Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 2001;7:176-80.
37. Kuwana M, Fujii T, Mimori T, Kaburaki J. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis: a report of two cases. Arthritis Rheum 1996;39:686-91. (Pubitemid 26119641)
38. Cohen IS, Mosher MB, O'Keefe EJ, Klaus SN, De Conti RC. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973; 107:553-5.
39. Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A. Bleomycin-induced scleroderma. J Rheumatol 1980;7:651-9.
40. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995;31A:2229-38. (Pubitemid 26050564)
41. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004;51:S73-6.
42. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 2003; 30:1341-3.
43. Abu-Shakra M, Lee P. Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy. J Rheumatol 1993;20:1601-3. (Pubitemid 24027342)
44. Colver GB, Rodger A, Mortimer PS, Savin JA, Neill SM, Hunter JA. Post-irradiation morphoea. Br J Dermatol 1989;120:831-5.
45. Anderson NE, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol 1988;24:559-67.
46. Lorusso L, Hart IK, Giometto B, Pezzani R, Broome JC, Gritti D, et al. Immunological features of neurological paraneoplastic syndromes. Int J Immunopathol Pharmacol 2004;17:135-44.
47. Vitaliani R, Zoccarato M, Giometto B. Diagnosis and treatment of paraneoplastic neurological syndromes. Curr Clin Pharmacol 2008;3:46-50. (Pubitemid 351210964)